Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial

As no specific pharmacological treatment has been validated for use in coronavirus disease 2019 (COVID-19), we aimed to assess the effectiveness of azithromycin (AZM) in these patients at a referral centre in Iran. An open-label, randomised controlled trial was conducted on patients with laboratory-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Antimicrob Agents
Autors principals: Sekhavati, Ehsan, Jafari, Fatemeh, SeyedAlinaghi, SeyedAhmad, Jamalimoghadamsiahkali, Saeidreza, Sadr, Sara, Tabarestani, Mohammad, Pirhayati, Mohammad, Zendehdel, Abolfazl, Manafi, Navid, Hajiabdolbaghi, Mahboubeh, Ahmadinejad, Zahra, Kouchak, Hamid Emadi, Jafari, Sirous, Khalili, Hosein, Salehi, Mohamadreza, Seifi, Arash, Golestan, Fereshteh Shahmari, Ghiasvand, Fereshteh
Format: Artigo
Idioma:Inglês
Publicat: Elsevier Ltd and International Society of Antimicrobial Chemotherapy. 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7445147/
https://ncbi.nlm.nih.gov/pubmed/32853672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ijantimicag.2020.106143
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars